 Terry Fry
Concepts (435)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 31 | 2023 | 184 | 7.360 |
Why?
| | T-Lymphocytes | 47 | 2023 | 1735 | 5.630 |
Why?
| | Antigens, CD19 | 22 | 2022 | 91 | 4.250 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 64 | 4.160 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 212 | 3.780 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 519 | 3.240 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2023 | 256 | 3.090 |
Why?
| | Receptors, Antigen, T-Cell | 16 | 2023 | 615 | 2.950 |
Why?
| | CD8-Positive T-Lymphocytes | 17 | 2023 | 687 | 2.770 |
Why?
| | Immunotherapy | 14 | 2023 | 473 | 2.770 |
Why?
| | Dendritic Cells | 11 | 2016 | 435 | 2.560 |
Why?
| | Cancer Vaccines | 9 | 2018 | 137 | 2.040 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2023 | 960 | 1.970 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 136 | 1.890 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 8 | 2022 | 11 | 1.770 |
Why?
| | Interleukin-7 | 18 | 2012 | 45 | 1.730 |
Why?
| | Lymphoma, B-Cell | 6 | 2022 | 87 | 1.490 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 237 | 1.350 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 19 | 1.290 |
Why?
| | Leukemia, Myeloid, Acute | 5 | 2023 | 533 | 1.290 |
Why?
| | Adoptive Transfer | 10 | 2019 | 194 | 1.210 |
Why?
| | Neoplasms | 13 | 2023 | 2089 | 1.060 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 1.040 |
Why?
| | Cytokines | 12 | 2022 | 1824 | 1.020 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 222 | 0.970 |
Why?
| | Dipeptides | 3 | 2014 | 47 | 0.960 |
Why?
| | H-Y Antigen | 5 | 2013 | 7 | 0.940 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.860 |
Why?
| | Animals | 51 | 2023 | 31570 | 0.820 |
Why?
| | Mice | 37 | 2023 | 14847 | 0.820 |
Why?
| | Tumor Escape | 3 | 2021 | 35 | 0.780 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 8 | 0.760 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 167 | 0.740 |
Why?
| | Immune System | 5 | 2010 | 171 | 0.730 |
Why?
| | Perforin | 1 | 2020 | 18 | 0.720 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 34 | 0.710 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 21 | 0.700 |
Why?
| | Retinoblastoma | 1 | 2020 | 27 | 0.700 |
Why?
| | WT1 Proteins | 2 | 2018 | 12 | 0.690 |
Why?
| | Humans | 97 | 2023 | 114080 | 0.690 |
Why?
| | Lymphoma | 2 | 2019 | 176 | 0.690 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 119 | 0.670 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 383 | 0.650 |
Why?
| | Erythropoietin | 1 | 2020 | 72 | 0.650 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 206 | 0.650 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 4682 | 0.650 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 377 | 0.650 |
Why?
| | Recurrence | 12 | 2023 | 925 | 0.640 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 149 | 0.630 |
Why?
| | Allergy and Immunology | 1 | 2019 | 51 | 0.610 |
Why?
| | Child | 34 | 2023 | 18408 | 0.560 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 338 | 0.550 |
Why?
| | Boron Compounds | 2 | 2014 | 17 | 0.550 |
Why?
| | Genetic Engineering | 2 | 2019 | 80 | 0.550 |
Why?
| | Calcitonin | 1 | 2016 | 23 | 0.540 |
Why?
| | Cell Lineage | 2 | 2016 | 308 | 0.530 |
Why?
| | Disease Models, Animal | 7 | 2020 | 3499 | 0.530 |
Why?
| | Cell Plasticity | 1 | 2016 | 23 | 0.520 |
Why?
| | Antigens, CD | 2 | 2017 | 440 | 0.520 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1036 | 0.510 |
Why?
| | Leukemia | 4 | 2023 | 208 | 0.510 |
Why?
| | Leukapheresis | 2 | 2017 | 21 | 0.510 |
Why?
| | Receptors, Cytokine | 1 | 2015 | 33 | 0.490 |
Why?
| | Mice, Knockout | 7 | 2020 | 2563 | 0.490 |
Why?
| | Donor Selection | 1 | 2015 | 65 | 0.480 |
Why?
| | Cell Line, Tumor | 12 | 2021 | 2699 | 0.470 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 63 | 0.450 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.450 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 43 | 0.450 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 186 | 0.450 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 55 | 0.440 |
Why?
| | Vaccination | 2 | 2012 | 1202 | 0.440 |
Why?
| | Apoptosis | 7 | 2019 | 2349 | 0.440 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 613 | 0.430 |
Why?
| | Female | 46 | 2021 | 59349 | 0.420 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 15 | 0.420 |
Why?
| | Boronic Acids | 1 | 2013 | 33 | 0.420 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 172 | 0.410 |
Why?
| | Adult | 29 | 2023 | 30395 | 0.410 |
Why?
| | Flow Cytometry | 6 | 2020 | 1075 | 0.400 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 385 | 0.400 |
Why?
| | Homeostasis | 4 | 2006 | 570 | 0.400 |
Why?
| | Young Adult | 17 | 2023 | 10459 | 0.390 |
Why?
| | Siblings | 4 | 2014 | 220 | 0.380 |
Why?
| | Antigens, CD34 | 2 | 2011 | 88 | 0.380 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 242 | 0.380 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 521 | 0.370 |
Why?
| | Living Donors | 3 | 2014 | 270 | 0.370 |
Why?
| | Lymphocyte Depletion | 7 | 2014 | 115 | 0.370 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 104 | 0.370 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 28 | 0.360 |
Why?
| | Antigen Presentation | 2 | 2009 | 188 | 0.360 |
Why?
| | Adolescent | 22 | 2023 | 17811 | 0.360 |
Why?
| | Male | 38 | 2021 | 55420 | 0.360 |
Why?
| | Immunologic Memory | 7 | 2016 | 313 | 0.340 |
Why?
| | Signal Transduction | 6 | 2019 | 4501 | 0.340 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 149 | 0.330 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 196 | 0.330 |
Why?
| | Gene Expression | 5 | 2020 | 1417 | 0.330 |
Why?
| | Child, Preschool | 15 | 2023 | 9121 | 0.320 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 65 | 0.320 |
Why?
| | Receptors, Interferon | 1 | 2009 | 47 | 0.310 |
Why?
| | Interleukin-10 | 1 | 2011 | 293 | 0.310 |
Why?
| | Thymus Gland | 3 | 2004 | 296 | 0.310 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 926 | 0.300 |
Why?
| | Mutation | 2 | 2015 | 3338 | 0.300 |
Why?
| | Remission Induction | 4 | 2017 | 233 | 0.300 |
Why?
| | Monocytes | 1 | 2011 | 503 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2019 | 637 | 0.290 |
Why?
| | Social Adjustment | 1 | 2008 | 56 | 0.290 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 380 | 0.290 |
Why?
| | Carcinoma | 1 | 2009 | 198 | 0.280 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 239 | 0.270 |
Why?
| | Receptors, Antigen | 2 | 2017 | 10 | 0.270 |
Why?
| | Allografts | 3 | 2018 | 121 | 0.270 |
Why?
| | Neuroblastoma | 2 | 2021 | 133 | 0.270 |
Why?
| | Prognosis | 7 | 2020 | 3315 | 0.270 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 850 | 0.260 |
Why?
| | Lymphopoiesis | 2 | 2006 | 24 | 0.260 |
Why?
| | Models, Immunological | 3 | 2020 | 90 | 0.250 |
Why?
| | Disease Progression | 5 | 2021 | 2371 | 0.250 |
Why?
| | Tissue Donors | 4 | 2018 | 314 | 0.250 |
Why?
| | Interferon-gamma | 1 | 2009 | 719 | 0.250 |
Why?
| | Mice, Transgenic | 6 | 2021 | 1947 | 0.250 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 148 | 0.250 |
Why?
| | Receptors, Interleukin-7 | 3 | 2011 | 25 | 0.240 |
Why?
| | Immunocompromised Host | 2 | 2010 | 192 | 0.240 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 175 | 0.240 |
Why?
| | Unrelated Donors | 3 | 2023 | 37 | 0.230 |
Why?
| | Macrophages | 1 | 2011 | 1259 | 0.220 |
Why?
| | Treatment Outcome | 11 | 2021 | 9051 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 337 | 0.220 |
Why?
| | Lentivirus | 3 | 2019 | 45 | 0.220 |
Why?
| | Regeneration | 2 | 2004 | 158 | 0.220 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 19 | 0.220 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1117 | 0.220 |
Why?
| | Interleukin-15 | 4 | 2014 | 74 | 0.210 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 42 | 0.200 |
Why?
| | Genetic Vectors | 3 | 2019 | 287 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 152 | 0.200 |
Why?
| | Mice, SCID | 4 | 2019 | 312 | 0.200 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 52 | 0.190 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 695 | 0.190 |
Why?
| | Anxiety | 1 | 2008 | 844 | 0.190 |
Why?
| | Gangliosides | 1 | 2021 | 18 | 0.190 |
Why?
| | Lymphopenia | 4 | 2011 | 49 | 0.190 |
Why?
| | Coculture Techniques | 2 | 2012 | 198 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 177 | 0.190 |
Why?
| | Bone Marrow | 3 | 2020 | 243 | 0.180 |
Why?
| | Recovery of Function | 1 | 2005 | 573 | 0.180 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 12 | 0.180 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 12 | 0.180 |
Why?
| | Exotoxins | 1 | 2020 | 14 | 0.180 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 62 | 0.180 |
Why?
| | Immunotoxins | 1 | 2020 | 33 | 0.180 |
Why?
| | B-Lymphocytes | 4 | 2018 | 763 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2021 | 98 | 0.170 |
Why?
| | Cyclophosphamide | 4 | 2023 | 214 | 0.170 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 96 | 0.170 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 552 | 0.170 |
Why?
| | Pediatrics | 1 | 2008 | 981 | 0.170 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 11 | 0.170 |
Why?
| | Bacterial Toxins | 1 | 2020 | 103 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1356 | 0.170 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 25 | 0.170 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 6 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 12 | 0.160 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Epitopes | 2 | 2018 | 434 | 0.160 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 428 | 0.160 |
Why?
| | Immunomodulation | 1 | 2019 | 84 | 0.160 |
Why?
| | Cell Membrane | 2 | 2020 | 670 | 0.160 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1003 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4392 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2020 | 217 | 0.150 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 14 | 0.150 |
Why?
| | History, 21st Century | 1 | 2019 | 160 | 0.150 |
Why?
| | Membrane Proteins | 1 | 2004 | 1016 | 0.150 |
Why?
| | Cryopreservation | 1 | 2019 | 92 | 0.150 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 56 | 0.150 |
Why?
| | History, 20th Century | 1 | 2019 | 265 | 0.150 |
Why?
| | Autoantigens | 2 | 2019 | 396 | 0.150 |
Why?
| | Graft Survival | 3 | 2011 | 443 | 0.150 |
Why?
| | Protein Domains | 1 | 2019 | 207 | 0.150 |
Why?
| | Chromatin | 2 | 2023 | 424 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2023 | 12521 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 221 | 0.150 |
Why?
| | Cell Division | 3 | 2012 | 754 | 0.140 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 57 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 2020 | 475 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2023 | 127 | 0.140 |
Why?
| | Immunophenotyping | 2 | 2020 | 274 | 0.140 |
Why?
| | Infant | 8 | 2018 | 7946 | 0.140 |
Why?
| | Cell Engineering | 1 | 2017 | 7 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 341 | 0.140 |
Why?
| | Lymph Nodes | 3 | 2013 | 415 | 0.140 |
Why?
| | Spine | 1 | 2018 | 136 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2013 | 2173 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 97 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 180 | 0.130 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 1875 | 0.130 |
Why?
| | Prospective Studies | 5 | 2023 | 6198 | 0.130 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.130 |
Why?
| | Stem Cell Niche | 1 | 2016 | 41 | 0.130 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 5 | 0.130 |
Why?
| | Clone Cells | 1 | 2016 | 247 | 0.130 |
Why?
| | Transcription Factors | 1 | 2023 | 1526 | 0.130 |
Why?
| | Gene Editing | 1 | 2016 | 57 | 0.130 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 12 | 0.130 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 13 | 0.120 |
Why?
| | Janus Kinases | 1 | 2015 | 12 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 350 | 0.120 |
Why?
| | Cell Line | 2 | 2017 | 2629 | 0.120 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 18 | 0.120 |
Why?
| | Erythrocytes | 1 | 2020 | 568 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 224 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2016 | 126 | 0.120 |
Why?
| | Virus Replication | 1 | 2017 | 395 | 0.120 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 6 | 0.120 |
Why?
| | Phenotype | 4 | 2019 | 2784 | 0.120 |
Why?
| | Calgranulin A | 1 | 2014 | 4 | 0.120 |
Why?
| | Calgranulin B | 1 | 2014 | 7 | 0.120 |
Why?
| | Growth | 1 | 1994 | 55 | 0.120 |
Why?
| | Survival Analysis | 2 | 2017 | 1206 | 0.120 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 77 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 59 | 0.110 |
Why?
| | Growth Disorders | 1 | 1994 | 77 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1144 | 0.110 |
Why?
| | Genome | 1 | 2016 | 269 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2015 | 186 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2314 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 70 | 0.110 |
Why?
| | Attitude to Health | 2 | 2008 | 398 | 0.110 |
Why?
| | Body Height | 1 | 1994 | 180 | 0.110 |
Why?
| | Transduction, Genetic | 3 | 2019 | 113 | 0.110 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 154 | 0.110 |
Why?
| | fas Receptor | 2 | 2019 | 91 | 0.110 |
Why?
| | Proteins | 1 | 2019 | 906 | 0.110 |
Why?
| | Animals, Congenic | 1 | 2012 | 9 | 0.110 |
Why?
| | Radiation Chimera | 1 | 2012 | 30 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 60 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 40 | 0.100 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 226 | 0.100 |
Why?
| | HIV Infections | 3 | 2008 | 2453 | 0.100 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 41 | 0.100 |
Why?
| | Brain Neoplasms | 2 | 2011 | 966 | 0.100 |
Why?
| | Tumor Burden | 1 | 2013 | 258 | 0.100 |
Why?
| | Treatment Failure | 2 | 2014 | 330 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 53 | 0.100 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 517 | 0.100 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 150 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2015 | 673 | 0.100 |
Why?
| | Body Weight | 2 | 2002 | 868 | 0.100 |
Why?
| | Chemokines | 1 | 2013 | 215 | 0.100 |
Why?
| | Blood Component Removal | 1 | 2011 | 26 | 0.090 |
Why?
| | Spleen | 2 | 2011 | 485 | 0.090 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.090 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 12 | 0.090 |
Why?
| | Alleles | 1 | 2013 | 789 | 0.090 |
Why?
| | Models, Biological | 2 | 2009 | 1611 | 0.090 |
Why?
| | Cytosine | 1 | 2010 | 43 | 0.090 |
Why?
| | Blood | 1 | 2011 | 94 | 0.090 |
Why?
| | Antiviral Agents | 2 | 2018 | 642 | 0.090 |
Why?
| | Organophosphonates | 1 | 2010 | 89 | 0.090 |
Why?
| | Acute Disease | 3 | 2023 | 909 | 0.090 |
Why?
| | Sarcoma | 1 | 2011 | 137 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 2009 | 30 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 3 | 2008 | 256 | 0.080 |
Why?
| | Lymphocyte Count | 2 | 2017 | 132 | 0.080 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 24 | 0.080 |
Why?
| | Virus Diseases | 1 | 2011 | 195 | 0.080 |
Why?
| | Hematopoietic System | 1 | 2008 | 8 | 0.080 |
Why?
| | Biomarkers | 2 | 2016 | 3397 | 0.080 |
Why?
| | Interleukin-12 | 1 | 2009 | 110 | 0.080 |
Why?
| | Sibling Relations | 1 | 2008 | 10 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 350 | 0.070 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 363 | 0.070 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 40 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 79 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2014 | 754 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 813 | 0.070 |
Why?
| | Psychology | 1 | 2008 | 82 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2014 | 3862 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 845 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2355 | 0.070 |
Why?
| | Recombinant Proteins | 5 | 2011 | 1228 | 0.070 |
Why?
| | Immune Tolerance | 2 | 2010 | 321 | 0.070 |
Why?
| | United States | 4 | 2018 | 12144 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 990 | 0.060 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 19 | 0.060 |
Why?
| | Obesity | 2 | 2022 | 2505 | 0.060 |
Why?
| | Hemostasis | 1 | 2004 | 64 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2023 | 21 | 0.050 |
Why?
| | CD3 Complex | 2 | 2017 | 92 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 381 | 0.050 |
Why?
| | Cohort Studies | 3 | 2014 | 4885 | 0.050 |
Why?
| | Body Mass Index | 1 | 2009 | 1957 | 0.050 |
Why?
| | Protein Binding | 2 | 2019 | 1888 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 115 | 0.050 |
Why?
| | United Kingdom | 2 | 2009 | 226 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 153 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 314 | 0.050 |
Why?
| | Middle Aged | 6 | 2021 | 26621 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2011 | 2122 | 0.050 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.050 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 64 | 0.040 |
Why?
| | Skin Transplantation | 1 | 2001 | 57 | 0.040 |
Why?
| | Ritonavir | 1 | 2001 | 71 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1014 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 135 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 327 | 0.040 |
Why?
| | Aged | 5 | 2021 | 18973 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 281 | 0.040 |
Why?
| | Hematopoiesis | 2 | 2016 | 170 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2019 | 19 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 2886 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2023 | 1696 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 628 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 8 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 14 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 802 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 24 | 0.040 |
Why?
| | Risk Factors | 4 | 2018 | 8612 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 73 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 18 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 241 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 170 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 21 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 30 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 397 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 25 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 29 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 105 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 260 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Weight Loss | 1 | 2002 | 642 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 143 | 0.040 |
Why?
| | Graft Rejection | 1 | 2001 | 511 | 0.040 |
Why?
| | Gene Order | 1 | 2017 | 24 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 183 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 347 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 207 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 589 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 863 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 618 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 229 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 6077 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 541 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 4598 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 98 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 5039 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 256 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 38 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 40 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 18 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 426 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 330 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 2764 | 0.030 |
Why?
| | CD28 Antigens | 1 | 2015 | 47 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 655 | 0.030 |
Why?
| | Exons | 1 | 2015 | 301 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 51 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 59 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2388 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 721 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 413 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 227 | 0.030 |
Why?
| | Reference Values | 1 | 1994 | 739 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 327 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 722 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 344 | 0.030 |
Why?
| | Aging | 1 | 2002 | 1612 | 0.030 |
Why?
| | Vidarabine | 1 | 2012 | 26 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 212 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 725 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 735 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 149 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 82 | 0.020 |
Why?
| | Vincristine | 1 | 2012 | 99 | 0.020 |
Why?
| | Rituximab | 1 | 2012 | 148 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 229 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 286 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 582 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 160 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 191 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 46 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1310 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 43 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 813 | 0.020 |
Why?
| | Risk | 1 | 2011 | 810 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 69 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 272 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2550 | 0.020 |
Why?
| | Mass Screening | 1 | 1994 | 979 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3039 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 290 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 220 | 0.020 |
Why?
| | Macaca fascicularis | 1 | 2007 | 50 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 211 | 0.020 |
Why?
| | HIV | 1 | 2008 | 208 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 131 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 590 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2009 | 287 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 170 | 0.020 |
Why?
| | Adiposity | 1 | 2009 | 458 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 266 | 0.020 |
Why?
| | Annexin A5 | 1 | 2004 | 22 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 641 | 0.010 |
Why?
| | Interleukins | 1 | 2006 | 236 | 0.010 |
Why?
| | Coloring Agents | 1 | 2004 | 72 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1690 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 102 | 0.010 |
Why?
| | Macaca mulatta | 1 | 2004 | 131 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 96 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 285 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1791 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 720 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 564 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 559 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 17 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1547 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 75 | 0.010 |
Why?
| | Colon | 1 | 2002 | 232 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 2958 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1128 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1757 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 4 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 36 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 32 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 1726 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1257 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 4404 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1633 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2273 | 0.010 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|